Stop Treating CDSCO Like a Lesser FDA — Here's the Real 2026 Comparison
CDSCO vs FDA in 2026 — The Honest Comparison Nobody Has Done
By Ankur Khare — Biomedical Engineer | Regulatory Affairs Specialist | Founder- MedReg Intel
Every Indian MedTech professional has an opinion about CDSCO.
Most of those opinions are formed by frustration — delayed approvals, deficiency notices, unclear timelines, and the persistent perception that getting a US FDA clearance is somehow more prestigious, more rigorous, and more internationally respected than a CDSCO registration.
And every foreign MedTech company eyeing the Indian market has a different kind of opinion — that CDSCO is unpredictable, understaffed, and impossible to navigate without insider connections.
Both sets of opinions contain some truth. Both miss a lot of it.
This article is the honest comparison that the Indian MedTech industry needs but rarely gets. Not a cheerleading piece for CDSCO. Not a dismissal of India's regulatory progress. A genuine, detailed, side-by-side analysis of where these two regulators stand in 2026 — what each does well, where each falls short, and what it actually means for manufacturers, importers, and startups operating in both markets.
If you are making decisions about regulatory strategy in India or the US in 2026, this is the comparison you need.
Setting the Context — Why This Comparison Matters Now
The comparison between CDSCO and FDA was largely academic five years ago. CDSCO was a relatively young regulator with limited enforcement capacity and a small fraction of FDA's resources and institutional history. FDA was the global gold standard, full stop.
2026 is a different landscape.
India's medical device market is now one of the top five globally by growth rate. The Indian government's Production Linked Incentive scheme for medical devices has attracted serious domestic and international manufacturing investment. CDSCO has undergone significant institutional development since MDR 2017 came into full effect, with expanded technical review capacity, a functioning online submission portal, and a growing international reputation as a reference regulator for several Asian and African markets.
Meanwhile FDA is navigating its own challenges — resource constraints, a 510(k) backlog that regularly exceeds industry expectations, the ongoing transition from legacy regulatory frameworks for software and AI-enabled devices, and increasing Congressional scrutiny of approval timelines and post-market surveillance effectiveness.
Neither regulator is standing still. And the gap between them is narrowing faster than most people in the industry acknowledge.
The Structural Comparison — How Each System Is Built
Before comparing outcomes, it is worth understanding how these two regulatory systems are structurally different, because the differences explain a lot of the performance gaps.
FDA's Structure
FDA's Center for Devices and Radiological Health — CDRH — is a standalone regulatory centre with over 1,000 employees dedicated specifically to medical device regulation. It has multiple review divisions organised by device category, a dedicated Office of Product Evaluation and Quality, a separate Office of Regulatory Affairs for enforcement, and a scientific review infrastructure that draws on decades of accumulated institutional knowledge.
FDA operates under a statutory framework — the Federal Food Drug and Cosmetic Act — that has been refined through decades of legislative amendments, court decisions, and guidance documents. The result is a system with enormous depth of precedent. When a company submits a 510(k), there are thousands of previously cleared predicates to reference, hundreds of device-specific guidance documents to follow, and a relatively predictable review process.
CDSCO's Structure
CDSCO operates under the Central Drugs Standard Control Organisation with a significantly smaller dedicated workforce for medical device regulation. The implementation of MDR 2017 created a modern risk-based regulatory framework comparable in principle to international standards, but the institutional infrastructure to implement that framework is still being built.
CDSCO's review capacity is distributed between the central office and State Licensing Authorities — SLAs — which handle Class A and Class B device licenses. This distributed model creates variability. The quality and consistency of regulatory review at the SLA level varies significantly across states, which is a challenge FDA's centralised structure does not face in the same way.
What CDSCO has that FDA does not is relative youth and therefore relative flexibility. MDR 2017 was designed from the ground up as a modern risk-based framework, incorporating lessons from EU MDR, ISO standards, and Global Harmonization Task Force principles. FDA, by contrast, is working within a statutory framework with deep legacy constraints that make rapid modernization genuinely difficult.
Device Classification — Similarities and Differences
Both systems use risk-based classification. The principles are similar. The implementation differs in important ways.
FDA Classification
FDA classifies devices into three classes. Class I devices are low risk, subject to general controls, and most are exempt from premarket notification. Class II devices are moderate risk and typically require 510(k) premarket notification demonstrating substantial equivalence to a legally marketed predicate device. Class III devices are high risk and require Premarket Approval — PMA — the most rigorous pathway, requiring clinical evidence of safety and effectiveness.
FDA's classification database contains thousands of device-specific classifications that manufacturers can reference directly. This specificity reduces classification ambiguity for established device types and makes the 510(k) predicate-finding process systematic rather than interpretive.
CDSCO Classification
MDR 2017 uses four classes — A, B, C, and D — mapped to low, low-moderate, moderate-high, and high risk respectively. The classification principles align with Global Harmonization Task Force guidance and are broadly comparable to international frameworks including EU MDR.
Where CDSCO's classification system is less developed than FDA's is in device-specific classification precedents. For novel device types — AI-enabled diagnostics, connected monitoring devices, combination products — classification under MDR 2017 requires applying general risk-based principles to specific device characteristics without the same depth of precedent that FDA's classification database provides.
CDSCO has been expanding its notified device list and classification guidance, but for manufacturers operating at the edge of existing device categories, classification certainty is higher with FDA than with CDSCO in 2026.
Verdict on Classification: FDA has the advantage of depth and specificity. CDSCO's framework is sound but the supporting infrastructure of precedents and device-specific guidance is still developing.
Approval Timelines — The Number That Everyone Wants
This is the comparison most people come to this article for. Let us look at it honestly.
FDA Timelines in 2026
The standard 510(k) review target is 90 days from acceptance to decision. In practice, the median total time from submission to final decision — including the time to reach acceptance and any additional information requests — has historically run between 150 and 250 days for standard 510(k)s. De Novo requests, used for novel low-to-moderate risk devices without a predicate, typically run 12 to 18 months. PMA applications for Class III devices average 180 days of review time after filing but total timelines including pre-submission meetings, clinical investigation, and review cycles routinely run three to five years.
FDA has made commitments under the Medical Device User Fee Agreement — MDUFA — to meet specific performance targets and has generally improved its 510(k) review times over the past several years. The system is not perfect but it is relatively predictable.
CDSCO Timelines in 2026
MDR 2017 specifies target timelines — 30 days for Class A, 60 days for Class B, 90 days for Class C, and 180 days for Class D from application receipt to decision. In practice, actual timelines are longer due to deficiency notice cycles, which pause the clock and effectively restart portions of the review.
For a well-prepared Class C application without deficiencies, realistic timelines in 2026 run approximately 6 to 12 months. For applications that receive multiple rounds of deficiency notices — which is common for first-time applicants — timelines of 18 to 24 months are not unusual.
For Class D devices and new drug-device combinations, CDSCO timelines are less predictable and can extend beyond 24 months in complex cases.
The honest picture: FDA is more predictable and its stated timelines are closer to actual timelines for straightforward applications. CDSCO's stated timelines are aspirational and the gap between target and actual is larger. However for the specific comparison of a standard moderate-risk device — Class II 510(k) versus Class C CDSCO registration — the actual timelines are not as dramatically different as the reputation gap suggests, particularly for well-prepared applications.
Verdict on Timelines: FDA has the advantage of predictability. CDSCO is improving but timeline variability remains a genuine challenge.
Clinical Evidence Requirements — Who Asks for More
This is where the comparison gets genuinely interesting and where the common perception is most misleading.
FDA Clinical Evidence Requirements
For 510(k) clearance — which covers the vast majority of medical devices cleared by FDA — clinical data is not always required. The substantial equivalence standard can often be met with bench testing, performance testing, and biocompatibility data without clinical studies. This is one of FDA's most significant advantages for manufacturers of established device types — a faster pathway that does not require the time and cost of formal clinical investigations for devices similar to existing cleared products.
For De Novo and PMA pathways, clinical evidence is required. FDA's clinical investigation requirements under IDE — Investigational Device Exemption — are rigorous, well-established, and supported by extensive guidance documentation.
CDSCO Clinical Evidence Requirements
For Class C and D devices, CDSCO requires clinical data. For imported devices, evidence from a reference regulator approval — including clinical data submitted to FDA or CE — can be used to support the CDSCO submission, which significantly reduces the additional clinical evidence burden for devices already approved in major markets.
For Indian-origin Class C devices without reference regulator approval, a formal clinical investigation conducted in India under CDSCO's clinical investigation requirements is mandatory. This is a more stringent requirement than FDA's 510(k) pathway for comparable risk-level devices and is one of the areas where CDSCO's requirements actually exceed FDA's for certain device types.
Verdict on Clinical Evidence: Counterintuitively, CDSCO's clinical evidence requirements for moderate-to-high risk devices without reference regulator approval are in some ways more demanding than FDA's 510(k) pathway. For devices with existing FDA or CE approvals, the burden is reduced through the reference regulator pathway.
Post-Market Surveillance — The Underappreciated Comparison
Post-market surveillance is where both regulators have significant room for improvement, but in different ways.
FDA Post-Market Surveillance
FDA's post-market surveillance system is the most developed in the world. The Medical Device Reporting — MDR — system collects adverse event reports from manufacturers, importers, and device user facilities. FDA's Unique Device Identification system enables device-level tracking through the supply chain. The National Evaluation System for health Technology — NEST — is building a real-world evidence infrastructure that will strengthen post-market surveillance significantly.
That said, FDA's post-market surveillance has been the subject of serious criticism. Studies have identified systematic underreporting in the MDR system. The alternative summary reporting pathway has been used by some manufacturers to reduce the visibility of individual adverse events. The 522 post-market surveillance study program is underused relative to the scale of the device market.
CDSCO Post-Market Surveillance
India's Materiovigilance Programme — MvPI — was established to collect adverse event reports for medical devices but its reporting rates remain significantly below what the scale of India's medical device market would predict. Awareness of reporting obligations among healthcare facilities and device users is low. CDSCO's enforcement of post-market surveillance plan requirements — mandatory for Class C and D device registrations — is developing.
MDR 2017's post-market surveillance requirements are comprehensive on paper — including Periodic Safety Update Reports, vigilance reporting timelines, and post-market clinical follow-up obligations. The challenge is implementation and enforcement at scale.
Verdict on Post-Market Surveillance: FDA has a significantly more developed post-market surveillance infrastructure. CDSCO's framework is sound but real-world implementation is at an earlier stage.
International Recognition — Whose Approval Opens More Doors
This is the area of comparison that matters most for manufacturers making strategic decisions about regulatory sequencing.
FDA's International Recognition
FDA clearance or approval is the most internationally recognised medical device regulatory decision in the world. In many markets — particularly in Asia, Latin America, and Africa — FDA clearance is accepted as supporting evidence for local registration, reducing documentation requirements and review timelines.
FDA clearance is also a commercial signal. In hospital procurement, FDA-cleared devices carry a perceived quality premium that influences purchasing decisions even in markets where FDA clearance is not legally required.
CDSCO's Growing International Recognition
CDSCO's international recognition has improved meaningfully since MDR 2017 came into effect. Several countries in South Asia and Africa now accept CDSCO registration as a reference approval for their own registration processes. India's membership in the International Medical Device Regulators Forum — IMDRF — signals CDSCO's integration into the global regulatory harmonisation conversation.
For manufacturers targeting other developing markets after India, CDSCO registration is increasingly useful as a reference approval. It is not yet at FDA's level of global recognition, but the trajectory is clearly upward.
Verdict on International Recognition: FDA has a significant and durable advantage. CDSCO's international standing is improving and will continue to improve as India's market importance grows.
Enforcement — Who Actually Follows Up
Regulatory approval means little if enforcement is weak. This is an area where honest comparison requires acknowledging uncomfortable realities.
FDA Enforcement
FDA's enforcement capability is substantial. Warning letters, import alerts, consent decrees, and device recalls are regularly issued and publicly tracked. FDA's inspection program — both domestic and international — creates meaningful compliance pressure on manufacturers. The consequences of an FDA warning letter are commercially significant — affecting not just the specific product but the company's entire portfolio and reputation.
CDSCO Enforcement
CDSCO's enforcement capacity has historically been a weakness relative to the scale of India's medical device market. Inspection frequency, particularly for post-market compliance, is lower than in developed regulatory systems. The commercial consequences of CDSCO non-compliance — while real — have historically been less immediate and visible than FDA consequences.
This is changing. CDSCO has strengthened its enforcement actions in recent years, particularly around unregistered devices entering the Indian market and violations of MDR 2017's post-market surveillance requirements. The direction of travel is clearly toward stronger enforcement, but the current state still represents a gap relative to FDA.
Verdict on Enforcement: FDA has a substantial advantage in enforcement capability and consistency. CDSCO is strengthening its enforcement posture but the gap remains significant in 2026.
The Regulatory Fee Comparison — What It Actually Costs
This is one area where CDSCO has an unambiguous and significant advantage for small manufacturers and startups.
FDA Fees in 2026
Under MDUFA V, the standard 510(k) application fee for large companies is approximately $22,000 USD — roughly ₹18 lakh at current exchange rates. Small businesses qualify for a reduced fee of approximately $5,500 — roughly ₹4.5 lakh. PMA application fees for large companies exceed $400,000 USD. Even with small business reductions, FDA fees represent a significant barrier for early-stage companies.
CDSCO Fees in 2026
CDSCO's application fees are a fraction of FDA's. Class C import license fees run in the range of ₹50,000 to ₹1,50,000 depending on the device and application type. Manufacturing license fees are similarly modest relative to the FDA equivalent.
The total cost of a CDSCO submission — including fees, consultant costs, and documentation preparation — is substantially lower than the equivalent FDA submission for comparable device classes. This makes CDSCO registration more accessible for domestic startups and small manufacturers than FDA clearance, which requires significant capital even before product development costs are considered.
Verdict on Fees: CDSCO has a clear and significant advantage for cost-accessible market entry, particularly for startups and small manufacturers.
The Summary Scorecard — Where Each Regulator Stands in 2026
Let me be direct about where each system excels and where each falls short.
FDA leads on timeline predictability, depth of classification precedents, international recognition, post-market surveillance infrastructure, and enforcement consistency. For manufacturers that can afford the cost and time, FDA clearance remains the highest quality signal a medical device can carry in global markets.
CDSCO leads on cost accessibility, regulatory framework modernity — MDR 2017 is a more contemporary framework than FDA's legacy structure in several respects — growing international recognition in emerging markets, and the sheer strategic importance of the Indian market itself. For any medical device company with global ambitions that does not include India, the strategy has a serious gap in it.
The honest conclusion is that these are not comparable systems in terms of institutional maturity and global recognition in 2026. FDA has a significant advantage on most dimensions. But CDSCO is a serious, improving, and increasingly important regulator that deserves to be evaluated on its actual current capabilities rather than its historical reputation.
What This Means for Your Regulatory Strategy
For Indian manufacturers targeting global markets, the strategic sequence that makes most sense in 2026 is to use CDSCO registration as your foundation, then pursue FDA clearance or EU CE marking for international expansion. The clinical and technical documentation prepared for a rigorous CDSCO Class C submission transfers meaningfully to FDA and EU submissions, reducing duplication.
For foreign manufacturers targeting India, the message is that CDSCO registration is a serious undertaking that deserves the same quality of regulatory strategy and documentation investment that you would bring to an FDA submission. Treating it as a secondary or easier version of your FDA submission is the single most common strategic error foreign manufacturers make in India — and it shows in their rejection and deficiency rates.
For investors and startup founders, the comparison matters because it reframes CDSCO registration from a bureaucratic hurdle into a genuine regulatory achievement. A company with a valid CDSCO Class C registration has demonstrated clinical safety and performance, quality management system compliance, and regulatory documentation capability. That is worth something — and increasingly, the global regulatory community recognises that it is worth something.
A Final Word on India's Regulatory Trajectory
CDSCO in 2026 is not the regulator it was in 2015. It is not yet the regulator it will be in 2035. It is a system in active, visible, and meaningful development — building institutional capacity, strengthening enforcement, deepening its international relationships, and working through the genuine challenges of regulating a massive and rapidly growing market with the resources available.
The comparison with FDA is useful not as a judgment but as a compass. The areas where CDSCO trails FDA most significantly — timeline predictability, post-market surveillance infrastructure, enforcement consistency — are precisely the areas where CDSCO's development efforts are most visible and where progress in the next five years is most likely.
India's medical device market is too important and too fast-growing for CDSCO to remain at its current developmental stage. The regulatory infrastructure will follow the market — it always does.
The question for manufacturers, investors, and regulatory professionals is not whether CDSCO will improve. It is whether your regulatory strategy is positioned to benefit from that improvement as it happens.
Stay Ahead of Regulatory Developments in India
MedReg Intel tracks CDSCO regulatory developments, MDR 2017 implementation updates, and India's evolving position in the global medical device regulatory landscape.
Explore our complete library of regulatory intelligence at medregintel.com
For regulatory strategy consultation or specific CDSCO guidance, reach out at ankur@medregintel.com
Ankur Khare is a Biomedical Engineer and Regulatory Affairs Specialist and the founder of MedReg Intel — India's dedicated medical device regulatory intelligence platform. The views expressed in this article represent the author's professional assessment based on publicly available regulatory information. This article does not constitute formal regulatory or legal advice.
Comments
Post a Comment